Post
by SleepWellCPAP » Thu Jul 11, 2013 5:25 pm
Regarding hourly compliance Wulfman is exactly right. Another point to make involves a doctor's follow up visit between the 30th and 90th day after start of treatment. It's the second part of compliance, mainly for the purposes of insurance coverage, that people tend to forget. Basically any treating physician, not necessarily the sleep doctor will meet face to face with the patient and indicate "pt is using and benefitting from the pap device" or something similar.
Regarding dementia, a few studies done in 2009 might be of interest. I'll paste them below. Not only should pressure therapy help your mother, it should indirectly help her caregiver, AKA your dad.
Good luck!
Jim
20275201 PMID: 19699148 Record Identifier: NIHMS140024; PMC2783482
Continuous positive airway pressure deepens sleep in patients with Alzheimer's disease and obstructive sleep apnea.
Cooke Jana R; Ancoli-Israel Sonia; Liu Lianqi; Loredo Jose S; Natarajan Loki; Palmer Barton S; He Feng; Corey-Bloom Jody
Department of Medicine, University of California San Diego, La Jolla, Ca 92093-0733, USA.
Sleep medicine ( Netherlands ) Dec 2009 , 10 (10) p1101-6 , OBJECTIVE: Patients with Alzheimer's disease (AD) and obstructive sleep apnea (OSA) experience disrupted sleep. This study examined the effect of continuous positive airway pressure (CPAP) on sleep parameters in AD patients with OSA. METHODS: A randomized placebo-controlled trial of 3 weeks of therapeutic CPAP (tCPAP) vs. 3 weeks placebo CPAP (pCPAP) followed by 3 weeks tCPAP in patients with AD and OSA. Polysomnography data from screening after one night and after 3 weeks of treatment were analyzed. Records were scored for percent of each sleep stage, total sleep time (TST), sleep efficiency (SE), sleep period (SP), time in bed (TIB), sleep onset (SO), wake time after sleep onset (WASO), and arousals. A randomized design comparing one night of pCPAP to tCPAP and a paired analysis combining 3 weeks of tCPAP were performed. RESULTS: Fifty-two participants (mean age=77.8 years, SD=7.3) with AD and OSA were included. After one treatment night, the tCPAP group had significantly less % Stage 1 (p=0.04) and more % Stage 2 sleep (p=0.02) when compared to the pCPAP group. In the paired analysis, 3 weeks of tCPAP resulted in significant decreases in WASO (p=0.005), % Stage 1 (p=0.001), arousals (p=0.005), and an increase in % Stage 3 (p=0.006). CONCLUSION: In mild to moderate AD patients with OSA, the use of tCPAP resulted in deeper sleep after just one night, with improvements maintained for 3 weeks.
Sustained use of CPAP slows deterioration of cognition, sleep, and mood inpatients with Alzheimer's disease and obstructive sleep apnea: a preliminary study.
Cooke JR, Ayalon L, Palmer BW, Loredo JS, Corey-Bloom J, Natarajan L, Liu L,
Ancoli-Israel S.
Department of Medicine, University of California, San Diego, CA, USA.
J Clin Sleep Med. 2009 Aug 15;5(4):305-9.
Comment in
J Clin Sleep Med. 2009 Aug 15;5(4):310.
INTRODUCTION: Obstructive sleep apnea (OSA) is common among patients with
Alzheimer's disease (AD). Untreated OSA exacerbates the cognitive and functional
deficits. Continuous positive airway pressure (CPAP) has recently been shown to
have beneficial effects on cognition in AD. Little attention has focused on the
long-term benefits of CPAP in these patients.
METHODS: This was an exploratory study of sustained CPAP use (mean use = 13.3
months, SD = 5.2) among a subset of participants from an initial 6-week
randomized clinical trial (RCT) of CPAP in patients with mild to moderate AD.
Follow-up included 5 patients who continued CPAP (CPAP+) after completion of the
RCT and 5 patients who discontinued CPAP (CPAP-), matched by time of completion
of the initial study. A neuropsychological test battery and sleep/mood
questionnaires were administered and effect sizes were calculated.
RESULTS: Even with a small sample size, sustained CPAP use resulted in
moderate-to-large effect sizes. Compared to the CPAP- group, the CPAP+ group
showed less cognitive decline with sustained CPAP use, stabilization of
depressive symptoms and daytime somnolence, and significant improvement in
subjective sleep quality. Caregivers of the CPAP+ group also reported that their
own sleep was better when compared to the final RCT visit and that their patients
psychopathological behavior was improved.
CONCLUSION: The results of this preliminary study raise the possibility that
sustained, long-term CPAP treatment for patients with AD and OSA may result in
lasting improvements in sleep and mood as well as a slowing of cognitive
deterioration. Prospective randomized controlled research trials evaluating these
hypotheses are needed.
Jim Swearingen
Author of the book Sleep Well & Feel Great with CPAP, a definitive guide
For a free copy inquire with your local county librarian
CPAPtalk featured - Also available through Barnes & Noble Booksellers